| Quartile of urinary A-megalin | P | |||||||
---|---|---|---|---|---|---|---|---|---|
Q1 (n = 11) | Q2 (n = 12) | Q3 (n = 11) | Q4 (n = 11) | ||||||
ΔeGFR (mL/min/1.73 m2) | −3.8 | ±6.7 | −15.2 | ±15.1 | −11.9 | ±18.0 | −20.8 | ±18.5 | 0.085a |
Estimated difference (95% CI) from Q1 (mL/min/1.73 m2) | |||||||||
 Crude | 0.00 | (reference) | −11.39 | (−24.30, 1.51)+ | −8.05 | (−21.23, 5.14) | −16.95 | (−30.13, −3.76)* | 0.018b |
 Adjusted | 0.00 | (reference) | −10.00 | (−22.29, 2.38) | −4.94 | (−17.73, 7.85) | −13.27 | (−26.17, −0.37)* | 0.064b |
Adverse renal events / person-days | 2 | / 194 | 7 | / 146 | 6 | / 129 | 9 | / 95 | Â |
Event rate (/10 person days) | 0.103 | 0.479 | 0.465 | 0.947 | Â | ||||
Hazard ratio (95% CI) | |||||||||
 Crude | 1.00 | (reference) | 4.25 | (0.88, 20.51)+ | 4.04 | (0.81, 20.09)+ | 7.24 | (1.55, 33.96)* | 0.008b |
 Adjusted | 1.00 | (reference) | 3.80 | (0.78, 18.48)+ | 3.03 | (0.60, 15.30) | 4.39 | (0.91, 21.13)+ | 0.093b |